Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AA Alcoa	$31.56 +4.5%	$27.75	$21.53 ▼ $47.77	$7.82B	2.25	5.64 million shs	8.88 million shs
HIMS Hims & Hers Health	$47.45 -1.1%	$51.44	$13.47 ▼ $72.98	$10.73B	2.02	23.24 million shs	24.20 million shs
LLY Eli Lilly and Company	$778.96 +0.4%	$777.35	$677.09 ▼ $972.53	$735.35B	0.4	3.66 million shs	1.98 million shs
LRN Stride	$137.49 -2.9%	$148.39	$63.25 ▼ $162.30	$6.16B	0.32	856,458 shs	1.31 million shs
NVDA NVIDIA	$157.25 +2.6%	$134.36	$86.62 ▼ $158.71	$3.74T	2.13	267.36 million shs	170.80 million shs
NVO Novo Nordisk A/S	$69.81 0.0%	$69.69	$57.00 ▼ $143.69	$311.75B	0.64	7.23 million shs	7.90 million shs

2025 Gold Forecast: A Perfect Storm for Demand

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AA Alcoa	+4.33%	+11.99%	+18.82%	+15.41%	-22.76%
HIMS Hims & Hers Health	-0.88%	+14.61%	-16.25%	+69.56%	+123.82%
LLY Eli Lilly and Company	+0.31%	-1.70%	+4.33%	-1.23%	-14.09%
LRN Stride	-3.07%	-2.82%	-13.18%	+5.17%	+100.01%
NVDA NVIDIA	+2.58%	+1.91%	+14.46%	+54.47%	+28.19%
NVO Novo Nordisk A/S	-0.06%	+3.62%	-4.08%	+4.07%	-51.18%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AA Alcoa	4.0116 of 5 stars	4.2	2.0	2.5	0.0	1.8	0.0	2.5
HIMS Hims & Hers Health	2.1239 of 5 stars	2.0	2.0	0.0	0.0	1.8	3.3	1.9
LLY Eli Lilly and Company	4.9882 of 5 stars	4.4	4.0	3.3	4.0	2.9	1.7	1.9
LRN Stride	1.891 of 5 stars	1.4	1.0	0.0	0.0	2.9	1.7	3.1
NVDA NVIDIA	4.8918 of 5 stars	3.5	5.0	1.7	3.0	2.7	2.5	1.9
NVO Novo Nordisk A/S	4.6888 of 5 stars	4.1	5.0	2.5	0.0	2.2	0.0	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AA Alcoa	2.42	Hold	$42.33	34.14% Upside
HIMS Hims & Hers Health	1.92	Reduce	$39.58	-16.58% Downside
LLY Eli Lilly and Company	2.75	Moderate Buy	$1,011.61	29.87% Upside
LRN Stride	2.71	Moderate Buy	$126.83	-7.75% Downside
NVDA NVIDIA	2.93	Moderate Buy	$175.78	11.78% Upside
NVO Novo Nordisk A/S	2.27	Hold	$112.00	60.44% Upside

Current Analyst Ratings Breakdown

Latest HIMS, NVO, LLY, AA, NVDA, and LRN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/25/2025	NVDA NVIDIA	Loop Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$175.00 ➝ $250.00
6/24/2025	HIMS Hims & Hers Health	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$45.00
6/24/2025	AA Alcoa	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$43.00 ➝ $38.00
6/23/2025	HIMS Hims & Hers Health	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell ➝ Sell
6/23/2025	HIMS Hims & Hers Health	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$30.00
6/23/2025	HIMS Hims & Hers Health	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Underperform ➝ Underperform
6/23/2025	HIMS Hims & Hers Health	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
6/20/2025	LLY Eli Lilly and Company	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$936.00
6/18/2025	AA Alcoa	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$25.00 ➝ $28.00
6/17/2025	NVDA NVIDIA	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$170.00 ➝ $200.00
6/16/2025	NVDA NVIDIA	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$175.00

(Data available from 7/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AA Alcoa	$11.90B	0.69	$3.79 per share	8.32	$19.96 per share	1.58
HIMS Hims & Hers Health	$1.48B	7.19	$0.35 per share	136.19	$2.16 per share	21.97
LLY Eli Lilly and Company	$45.04B	16.39	$14.29 per share	54.51	$15.03 per share	51.83
LRN Stride	$2.04B	2.93	$7.08 per share	19.41	$27.19 per share	5.06
NVDA NVIDIA	$130.50B	29.40	$3.14 per share	50.14	$3.44 per share	45.71
NVO Novo Nordisk A/S	$42.12B	7.40	$3.90 per share	17.90	$4.66 per share	14.98

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AA Alcoa	$60M	$3.32	9.51	9.96	0.18	6.79%	18.56%	7.02%	7/16/2025 (Estimated)
HIMS Hims & Hers Health	$126.04M	$0.69	68.77	91.25	1.76	9.24%	22.75%	15.51%	8/4/2025 (Estimated)
LLY Eli Lilly and Company	$10.59B	$12.29	63.38	25.03	1.13	22.67%	85.51%	15.74%	8/7/2025 (Estimated)
LRN Stride	$204.18M	$6.41	21.45	18.81	0.91	13.10%	23.36%	14.66%	8/5/2025 (Estimated)
NVDA NVIDIA	$72.88B	$3.10	50.73	39.51	1.36	51.69%	105.09%	72.19%	8/27/2025 (Estimated)
NVO Novo Nordisk A/S	$14.64B	$3.38	20.65	14.98	1.24	34.52%	80.94%	24.23%	8/6/2025 (Estimated)

Latest HIMS, NVO, LLY, AA, NVDA, and LRN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/16/2025	Q2 2025	AA Alcoa	$0.87	N/A	N/A	N/A	$2.96 billion	N/A
5/28/2025	Q1 2026	NVDA NVIDIA	$0.87	$0.81	-$0.06	$0.76	$43.09 billion	$44.06 billion
5/7/2025	Q1 2025	NVO Novo Nordisk A/S	$0.92	$0.92	N/A	$0.92	N/A	$11.87 billion
5/5/2025	Q1 2025	HIMS Hims & Hers Health	$0.12	$0.20	+$0.08	$0.20	$535.21 million	$586.01 million
5/1/2025	Q1 2025	LLY Eli Lilly and Company	$4.64	$3.34	-$1.30	$3.06	$12.77 billion	$12.73 billion
4/29/2025	Q3 2025	LRN Stride	$2.09	$2.02	-$0.07	$2.02	$591.15 million	$613.38 million
4/16/2025	Q1 2025	AA Alcoa	$1.73	$2.15	+$0.42	$2.07	$3.58 billion	$3.37 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AA Alcoa	$0.40	1.27%	N/A	12.05%	N/A
HIMS Hims & Hers Health	N/A	N/A	N/A	N/A	N/A
LLY Eli Lilly and Company	$6.00	0.77%	N/A	48.82%	11 Years
LRN Stride	N/A	N/A	N/A	N/A	N/A
NVDA NVIDIA	$0.04	0.03%	N/A	1.29%	1 Years
NVO Novo Nordisk A/S	$1.64	2.35%	N/A	48.52%	N/A

Latest HIMS, NVO, LLY, AA, NVDA, and LRN Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/23/2025	LLY Eli Lilly and Company	quarterly	$1.50	0.78%	8/15/2025	8/15/2025	9/10/2025
5/28/2025	NVDA NVIDIA	quarterly	$0.01	0.03%	6/11/2025	6/11/2025	7/3/2025
5/5/2025	LLY Eli Lilly and Company	quarterly	$1.50	0.73%	5/16/2025	5/16/2025	6/10/2025
5/9/2025	AA Alcoa	quarterly	$0.10	1.54%	5/20/2025	5/20/2025	6/6/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AA Alcoa	0.43	1.71	1.00
HIMS Hims & Hers Health	N/A	1.59	1.32
LLY Eli Lilly and Company	2.18	1.37	1.06
LRN Stride	0.33	5.61	5.53
NVDA NVIDIA	0.10	3.39	2.96
NVO Novo Nordisk A/S	0.70	0.74	0.56

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AA Alcoa	N/A
HIMS Hims & Hers Health	63.52%
LLY Eli Lilly and Company	82.53%
LRN Stride	98.24%
NVDA NVIDIA	65.27%
NVO Novo Nordisk A/S	11.54%

Insider Ownership

Company	Insider Ownership
AA Alcoa	N/A
HIMS Hims & Hers Health	13.71%
LLY Eli Lilly and Company	0.13%
LRN Stride	3.00%
NVDA NVIDIA	4.17%
NVO Novo Nordisk A/S	0.07%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AA Alcoa	13,900	258.90 million	N/A	Optionable
HIMS Hims & Hers Health	1,637	223.83 million	193.15 million	Optionable
LLY Eli Lilly and Company	47,000	947.74 million	946.50 million	Optionable
LRN Stride	7,800	43.52 million	42.22 million	Optionable
NVDA NVIDIA	36,000	24.40 billion	23.38 billion	Optionable
NVO Novo Nordisk A/S	77,349	4.47 billion	4.46 billion	Optionable

HIMS, NVO, LLY, AA, NVDA, and LRN Headlines

Recent News About These Companies

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

July 2 at 9:51 AM | zacks.com

WCM Investment Management LLC Purchases 104,733 Shares of Novo Nordisk A/S (NYSE:NVO)

July 2 at 8:25 AM | marketbeat.com

Harbour Trust & Investment Management Co Purchases 22,195 Shares of Novo Nordisk A/S (NYSE:NVO)

July 2 at 7:53 AM | marketbeat.com

Pictet North America Advisors SA Has $5.01 Million Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

July 2 at 7:20 AM | marketbeat.com

Novo Nordisk A/S (NYSE:NVO) Shares Sold by Vontobel Holding Ltd.

July 2 at 6:04 AM | marketbeat.com

Novo Nordisk A/S (NYSE:NVO) Receives Consensus Recommendation of "Hold" from Analysts

July 2 at 2:42 AM | marketbeat.com

India’s Biocon Aims to Lead Copycat Wegovy Sales in Canada From Next Year

July 1 at 7:48 PM | financialpost.comF

Novo Nordisk (NVO) Ascends While Market Falls: Some Facts to Note

July 1 at 6:45 PM | zacks.com

Novo Nordisk: The Pullback Is Noise - The Buy Case Is Stronger Than Ever

July 1 at 1:04 PM | seekingalpha.com

Mizuho's Jared Holz: Novo Nordisk is trying to come up with strategies to regain market share

July 1 at 12:05 PM | youtube.comY

Novo Nordisk A/S (NYSE:NVO) Shares Purchased by DAVENPORT & Co LLC

July 1 at 8:48 AM | marketbeat.com

Insight: How Novo Nordisk misread the US market for its weight loss sensation

July 1 at 6:07 AM | reuters.com

Canandaigua National Bank & Trust Co. Sells 8,296 Shares of Novo Nordisk A/S (NYSE:NVO)

July 1 at 5:40 AM | marketbeat.com

Essex Financial Services Inc. Reduces Holdings in Novo Nordisk A/S (NYSE:NVO)

July 1 at 4:59 AM | marketbeat.com

Novo Nordisk A/S (NVO) is Attracting Investor Attention: Here is What You Should Know

June 30 at 10:00 AM | zacks.com

Farmers & Merchants Trust Co of Chambersburg PA Trims Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

June 30 at 9:03 AM | marketbeat.com

Novo Nordisk, Eli Lilly face first major obesity drug rival in China as Innovent gains approval for mazdutide

June 30 at 3:44 AM | msn.com

7 Killer European Stocks To Buy In July

June 29, 2025 | 247wallst.com

3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking (NVO)

...

June 29, 2025 | marketbeat.com

Mmbg Investment Advisors CO. Purchases 12,320 Shares of Novo Nordisk A/S (NYSE:NVO)

June 29, 2025 | marketbeat.com

Novo Nordisk A/S (NYSE:NVO) Shares Sold by Naviter Wealth LLC

June 29, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
3 Stocks Getting Rare Double Upgrades From Analysts
By Chris Markoch | June 6, 2025
View 3 Stocks Getting Rare Double Upgrades From Analysts
3 Catalysts in 7 Days: Archer's Growth Story Just Accelerated
By Jeffrey Neal Johnson | June 18, 2025
View 3 Catalysts in 7 Days: Archer's Growth Story Just Accelerated
AST SpaceMobile’s Star Is Rising: Get in While It’s Still Cheap!
By Thomas Hughes | June 16, 2025
View AST SpaceMobile’s Star Is Rising: Get in While It’s Still Cheap!
Best Dollar Store Stock to Buy: Dollar Tree or Dollar General?
By Thomas Hughes | June 5, 2025
View Best Dollar Store Stock to Buy: Dollar Tree or Dollar General?

HIMS, NVO, LLY, AA, NVDA, and LRN Company Descriptions

Alcoa NYSE:AA

$31.56 +1.36 (+4.50%)

Closing price 07/2/2025 03:59 PM Eastern

Extended Trading

$31.56 0.00 (-0.02%)

As of 07:01 AM Eastern

Alcoa Corporation, together with its subsidiaries, produces and sells bauxite, alumina, and aluminum products in the United States, Spain, Australia, Iceland, Norway, Brazil, Canada, and internationally. The company operates through two segments, Alumina and Aluminum. It engages in bauxite mining operations; and processes bauxite into alumina and sells it to customers who process it into industrial chemical products, as well as aluminum smelting and casting businesses. The company offers primary aluminum in the form of alloy ingot or value-add ingot to customers that produce products for the transportation, building and construction, packaging, wire, and other industrial markets; and flat-rolled aluminum in the form of sheet, which is sold primarily to customers that produce beverage and food cans. In addition, it owns hydro power plants that generates and sells electricity in the wholesale market to traders, large industrial consumers, distribution companies, and other generation companies. The company was formerly known as Alcoa Upstream Corporation and changed its name to Alcoa Corporation in October 2016. The company was founded in 1886 and is headquartered in Pittsburgh, Pennsylvania.

Hims & Hers Health NYSE:HIMS

$47.45 -0.51 (-1.06%)

Closing price 07/2/2025 03:59 PM Eastern

Extended Trading

$47.51 +0.06 (+0.13%)

As of 07:06 AM Eastern

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Eli Lilly and Company NYSE:LLY

$778.96 +3.06 (+0.39%)

Closing price 07/2/2025 03:59 PM Eastern

Extended Trading

$780.30 +1.34 (+0.17%)

As of 07:06 AM Eastern

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Stride NYSE:LRN

$137.49 -4.06 (-2.87%)

Closing price 07/2/2025 03:59 PM Eastern

Extended Trading

$137.46 -0.03 (-0.02%)

As of 07:03 AM Eastern

Stride, Inc., a technology-based education service company, engages in the provision of proprietary and third-party online curriculum, software systems, and educational services in the United States and internationally. Its technology-based products and services enable clients to attract, enroll, educate, track progress, support, and facilitate individualized learning for students. The company offers integrated package of systems, services, products, and professional expertise to support a virtual or blended public school; software and services to schools and school districts; individual online courses and supplemental educational products; and products and services for the general education market focused on subjects, including math, English, science, and history for kindergarten through twelfth grade students. It also provides career learning products and services that are focused on developing skills to enter in industries, including information technology, health care, and business; and operates tuition-based private schools. In addition, the company offers focused post-secondary career learning programs, which include skills training for software engineering, healthcare, and medical fields to adult learners under Galvanize, Tech Elevator, and MedCerts brand names, as well as provides staffing and talent development services to employers. It serves public and private schools, school districts, charter boards, consumers, employers, and government agencies. The company was formerly known as K12 Inc. and changed its name to Stride, Inc. in December 2020. Stride, Inc. was incorporated in 1999 and is headquartered in Reston, Virginia.

NVIDIA NASDAQ:NVDA

$157.25 +3.95 (+2.58%)

Closing price 07/2/2025 04:00 PM Eastern

Extended Trading

$157.11 -0.14 (-0.09%)

As of 07:07 AM Eastern

NVIDIA Corporation provides graphics and compute and networking solutions in the United States, Taiwan, China, Hong Kong, and internationally. The Graphics segment offers GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, and solutions for gaming platforms; Quadro/NVIDIA RTX GPUs for enterprise workstation graphics; virtual GPU or vGPU software for cloud-based visual and virtual computing; automotive platforms for infotainment systems; and Omniverse software for building and operating metaverse and 3D internet applications. The Compute & Networking segment comprises Data Center computing platforms and end-to-end networking platforms, including Quantum for InfiniBand and Spectrum for Ethernet; NVIDIA DRIVE automated-driving platform and automotive development agreements; Jetson robotics and other embedded platforms; NVIDIA AI Enterprise and other software; and DGX Cloud software and services. The company's products are used in gaming, professional visualization, data center, and automotive markets. It sells its products to original equipment manufacturers, original device manufacturers, system integrators and distributors, independent software vendors, cloud service providers, consumer internet companies, add-in board manufacturers, distributors, automotive manufacturers and tier-1 automotive suppliers, and other ecosystem participants. NVIDIA Corporation was incorporated in 1993 and is headquartered in Santa Clara, California.

Novo Nordisk A/S NYSE:NVO

$69.81 -0.01 (-0.01%)

Closing price 07/2/2025 03:59 PM Eastern

Extended Trading

$69.90 +0.09 (+0.13%)

As of 07:06 AM Eastern

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare MarketRank™

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest HIMS, NVO, LLY, AA, NVDA, and LRN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest HIMS, NVO, LLY, AA, NVDA, and LRN Earnings

Compare Dividends

Latest HIMS, NVO, LLY, AA, NVDA, and LRN Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

HIMS, NVO, LLY, AA, NVDA, and LRN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

HIMS, NVO, LLY, AA, NVDA, and LRN Company Descriptions

Alcoa NYSE:AA

Hims & Hers Health NYSE:HIMS

Eli Lilly and Company NYSE:LLY

Stride NYSE:LRN

NVIDIA NASDAQ:NVDA

Novo Nordisk A/S NYSE:NVO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools